First-time biopharma launchers face interconnected challenges, including limited capital, lengthy preparation timelines, regulatory uncertainty and greater pressure to meet commercial forecasts. This white paper examines why traditional launch approaches often fall short and outlines practical strategies for building the right capabilities at the right time. Readers will learn how earlier planning, integrated execution and a flexible partnership model can help reduce launch risk, improve capital and time efficiency, and position a product to achieve its full commercial potential. [Transforma...WP_TL_0226 | PDF]
Sanofi is exploring a $35B–$43B takeover of Insmed and its blockbuster lung drug Brinsupri as the French pharma giant braces for Dupixent’s looming patent expiration.
Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.
As specialty drug complexity grows, agentic technology puts the right access, adherence, and affordability resources at the provider’s fingertips at prescribing.